Biofrontera AG (BFFTF) Research

Biofrontera AG operates as a biopharmaceutical enterprise, dedicated to the exploration, evolution, and commercialization of dermatological therapies. Its flagship offerings, Ameluz and the BF-RhodoLED lamp, are utilized for treating mild to moderate actinic keratoses on the face and scalp, managing field cancerization, and addressing life-threatening squamous cell carcinoma. The company is also advancing RhodoLED XL, intended for extensive interspersed lesions, and provides Belixos, an innovative cosmetic product designed for sensitive and irritated skin. Furthermore, Biofrontera develops Xepi, an agent targeting infections from antibiotic-resistant bacteria. The company primarily markets its solutions across the United States, Europe, and Israel, and maintains a collaborative and partnership agreement with Maruho Co., Ltd. Founded in 1997, Biofrontera AG's corporate headquarters are situated in Leverkusen, Germany.

Market snapshot

Symbol
BFFTF
Price
$0.33
Day change
-95.24%
Market cap
$12.6M
P/E ratio
-1.04x
52-week range
0.33-22.68
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Peer companies

  • Antisense Therapeutics Limited (ATHJF)
  • TPCO Holding Corp. (GRAMF)
  • The Hempshire Group, Inc. (HMPSF)
  • Lifeist Wellness Inc. (NXTTF)
  • PharmChem, Inc. (PCHM)
  • RAMM Pharma Corp. (RAMMF)
  • Red White & Bloom Brands Inc. (RWBYF)
  • Sorrento Therapeutics, Inc. (SRNEQ)

Open Biofrontera AG (BFFTF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.